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Abstract
Background: An important component of the policy to deal with the H1N1 pandemic in 2009 was to develop
and implement vaccination. Since pregnant women were found to be at particular risk of severe morbidity and
mortality, the World Health Organization and the European Centre for Disease Prevention and Control advised
vaccinating pregnant women, regardless of trimester of pregnancy. This study reports a survey of vaccination
policies for pregnant women in European countries.
Methods: Questionnaires were sent to European competent authorities of 27 countries via the European
Medicines Agency and to leaders of registries of European Surveillance of Congenital Anomalies in 21 countries.
Results: Replies were received for 24 out of 32 European countries of which 20 had an official pandemic
vaccination policy. These 20 countries all had a policy targeting pregnant women. For two of the four countries
without official pandemic vaccination policies, some vaccination of pregnant women took place. In 12 out of 20
countries the policy was to vaccinate only second and third trimester pregnant women and in 8 out of 20
countries the policy was to vaccinate pregnant women regardless of trimester of pregnancy. Seven different
vaccines were used for pregnant women, of which four contained adjuvants. Few countries had mechanisms to
monitor the number of vaccinations given specifically to pregnant women over time. Vaccination uptake varied.
Conclusions: Differences in pandemic vaccination policy and practice might relate to variation in perception of
vaccine efficacy and safety, operational issues related to vaccine manufacturing and procurement, and vaccination
campaign systems. Increased monitoring of pandemic influenza vaccine coverage of pregnant women is
recommended to enable evaluation of the vaccine safety in pregnancy and pandemic vaccination campaign
effectiveness.
Background
On 24 March 2009, an outbreak of novel H1N1 influenza
A, now commonly referred to as the 2009 H1N1 pan-
demic influenza or simply the swine flu, was identified in
Mexico. The new virus quickly spread and on the 11th
June 2009, the World Health Organization (WHO) raised
the pandemic level to 6, indicating the first widespread
influenza pandemic since the 1968 H3N2 Hong Kong flu.
European Centre for Disease Prevention and Control
(ECDC) and the WHO defined clinical and pharmacologi-
cal advisory management guidelines for managing this
pandemic, while European national authorities were
responsible for developing national vaccination policies.
During seasonal influenza and previous influenza pan-
demics, pregnant women have been at increased risk of
adverse health outcomes [1,2]. Preliminary data collected
between April 2009 and July 2009 from Australia and the
USA suggested pregnant women in the second or third tri-
mester who had H1N1 influenza, especially if suffering
from co-morbidities, were particularly vulnerable to mor-
tality and severe morbidity [3,4]. Both the European Com-
mission (EC)[5] and the WHO [6] advised vaccination of
pregnant women against the 2009 H1N1 pandemic swine
flu, regardless of stage of pregnancy.
While policy advice was based on the available safety
information in 2009, pharmacovigilance studies will need
to verify the presumed safety of the pandemic vaccine and
the adjuvants used. European Surveillance of Congenital
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Anomalies (EUROCAT), a network of population based
congenital anomaly registers in Europe currently surveying
31% of European Union births [7], is participating in safety
monitoring of the pandemic vaccines use in pregnancy
with regard to congenital anomalies. This study reports
the results of a survey undertaken to gather data regarding
when and where pregnant women, and women of child-
bearing age (WCBA), received pandemic influenza vac-
cine, in order to interpret EUROCAT prevalence data on
congenital anomalies. WCBA are relevant for this study
since women may receive the vaccine before they know
they are pregnant. The purpose of this paper is to describe
the vaccination policies in European countries to enable
discussion and reflection on the differences between pan-
demic vaccination policies and vaccination coverage of
pregnant women between European countries.
Methods
A questionnaire regarding vaccination policy and anti-
viral use was sent out to EUROCAT registry leaders
April 23rd, 2010, with a reminder on May 18th, 2010.
EUROCAT registries are situated in 17 EU countries and
in Croatia, Norway, Switzerland and Ukraine. The
EUROCAT-questionnaire contained eight questions with
regard to antiviral use and vaccination policy and offer/
uptake for pregnant women and WCBA. The majority of
EUROCAT registry leaders who completed the question-
naire were public health specialists and clinicians who
did not have specific responsibilities related to vaccina-
tion policy in their countries. Respondents were asked to
estimate vaccination coverage of pregnant women in
their areas using broad bands (0-24%, 25-49%, ...) with
free space for more specific information and references
where further data could be obtained. Some EUROCAT
registries also collect individual exposure data on conge-
nital anomaly cases but this was not yet available at the
time of the survey.
Within the European regulatory system it is possible to
collect or exchange information from other member
states by circulating a request for Non-Urgent Informa-
tion (NUI) between the competent authorities and the
European Medicines Agency (EMA) [8]. The European
regulatory system consists of the 27 EU member states
plus Iceland, Liechtenstein and Norway. On July 23rd,
2010, a NUI was circulated to 27 Member States’ repre-
sentatives at the Pharmacovigilance Working Party
(PhVWP) of the Committee for Medicinal Products for
Human use (CHMP) of the EMA to collect information
on pandemic vaccination policies and policies for anti-
viral use with regard to pregnant women and WCBA, to
complement the EUROCAT survey. The NUI contained
seven questions. The NUI requested weekly or monthly
data on numbers of vaccinated pregnant women instead
of banded coverage estimates. A second NUI was
circulated on March 14th 2011 to confirm the data. In
addition to the two survey questionnaires, we followed
up any references given by respondents and conducted
literature and conference abstract searches - eight addi-
tional relevant items were added from these sources
[9-16].
Role of the funding source
The study funder took no part in study design; in the
collection, analysis and interpretation of data in the
writing of the report; and in the decision to submit the
paper for publication.
Ethics
Under University of Ulster’s ethical review policy this
type of study does not require ethical review, and we
have overarching ethical approval for activities carried
out under EUROCAT.
Results
A total of 16 countries of the 27 who were sent a NUI by
EMA returned a complete response. One additional coun-
try sent a partial reply during the confirmation process.
The completed EUROCAT questionnaire was returned
from 17 of 21 countries covered by EUROCAT, giving a
combined total of 24 responding countries (table 1). Of
the 27 EU states Bulgaria, Cyprus, Estonia, Lithuania, Lux-
embourg and Romania were not covered by the combined
replies.
Pandemic vaccination policies in Europe for pregnant
women
Of the 24 European countries covered by the combined
questionnaires, 20 countries (83%) reported having an
official vaccination policy against pandemic swine flu for
pregnant women (table 2). In 12 of these 20 countries,
this policy did not include first trimester pregnant
women (table 2). In Croatia, despite lack of an official
policy, pregnant women in the second or third trimester
of pregnancy could apply for vaccination via health
insurance. In Czech Republic while there was no official
vaccination policy, a small number of pregnant women
were vaccinated-In Latvia and Poland there was no
recorded vaccination of pregnant women.
In total 7 different vaccines were used for pregnant
women, of which 4 were adjuvanted and 3 were non-
adjuvanted (table 2). Vaccination campaigns of pregnant
women were initiated between 28th September 2009
(Hungary) and 27th December 2009 (Malta). (Data not
shown) Respondents from eight countries were unable to
provide detailed information on when the vaccination
campaign of pregnant women started. Note the initiation
of the vaccination campaign does not necessarily corre-
spond to initiation of vaccination.
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Pandemic vaccination policies in Europe for women of
childbearing age
WCBA were not distinguished from the general popula-
tion in any country regarding pandemic vaccination policy.
In 14 out of 24 European countries (58%) the pandemic
vaccine was offered to priority groups first (table 2) and
then offered to the general population. In six out of 24
European countries (25%) the pandemic vaccine was
offered to priority groups only and not offered to the gen-
eral population. In Croatia and Czech Republic, the gen-
eral population could apply for vaccination despite the
absence of an official vaccination policy. In Latvia and
Poland, no vaccination took place.
Data on exposure of pregnant women to swine flu
vaccine
For five out of 20 countries with an official vaccination
policy, no exposure data was available regarding pregnant
women. Other countries had a variety of data including
weekly or monthly vaccination rates or total number of
pregnant women vaccinated or vaccine doses distributed,
registers for pregnant women who had been given vac-
cine, surveys of general practitioners or monitoring of
specific areas or hospitals (table 3). Vaccination uptake
rates above 50% have been reported from 3 countries
(Finland, Ireland and Norway; Table 3).
Data on exposure of women of childbearing age to swine
flu vaccine
Four countries were able to provide a figure on WCBA
vaccinated (table 3).
Discussion
The majority of countries (83% of 24 respondents) had an
official vaccination policy for pregnant women. No replies
were received from nine countries and it is possible that
response bias results from smaller countries and countries
without vaccination policies being less likely to respond.
Twenty one countries out of the 27 in the EU, correspond-
ing to 93% of the member population, were covered by the
combined responses to both questionnaires.
Some countries had existing advance purchase agree-
ments with pharmaceutical companies which allowed
early procurement. A lack of capacity to identify and
prioritise key population groups quickly may also have
influenced policy decisions. Public perceptions, which can
be influenced by certain key events in a population, may
be significant. For example, in the Czech Republic, a pre-
vious key event involving vaccines contaminated with
deadly live H5N1 avian flu virus, might have influenced
the decision not to formulate an official vaccination policy
[17].
A larger number of European countries have a vaccina-
tion policy for pregnant women against pandemic influ-
enza than against seasonal influenza. Ten out of 27 (37%)
European countries recommended vaccination against
seasonal influenza for pregnant women during the 2008-
9 influenza season: Austria, Belgium, Cyprus, Denmark,
Estonia, Ireland, Italy, Portugal, Slovakia and Spain [18].
None of these countries could provide information on
vaccine coverage of pregnant women. All these countries
had a pandemic vaccination policy in force during the
pandemic influenza, and it is possible that this was facili-
tated by the previous seasonal flu policy. Both in Canada
Table 1 Response to the questionnaires by competent
authorities and EUROCAT members
Country Sources
EUROCAT EMA-NUI
Austria ⊠ □
Belgium ⊠ ⊠1
Bulgaria □
Cyprus □
Czech Republic ⊠ □
Croatia ⊠
Denmark ⊠ ⊠
Estonia □
Finland ⊠ ⊠
France ⊠ ⊠
Germany ⊠ □
Greece ⊠
Hungary □ ⊠
Iceland
Ireland ⊠ ⊠
Italy □ ⊠
Latvia ⊠
Lithuania □
Luxembourg □
Malta ⊠
Netherlands ⊠ ⊠
Norway ⊠ ⊠
Poland ⊠ □
Portugal ⊠ ⊠
Romania □
Slovakia ⊠
Slovenia ⊠
Spain ⊠ ⊠
Sweden □ ⊠
Switzerland ⊠
Ukraine □
United Kingdom ⊠ ⊠
1Belgium replied to the second NUI circulated March 14th, 2011.
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and the United states, vaccination of pregnant women is
recommended during the influenza season, while in Aus-
tralia, vaccination of pregnant women in the second or
third trimester of pregnancy is recommended during the
influenza season [1].
Vaccination policy only partially determines what hap-
pens in a country. Data collected by the questionnaires
demonstrated that countries with similar vaccination
policies achieve very different vaccination rates. For
example Italy and the Netherlands had similar vaccina-
tion policies but 23,016 women in the second and third
trimester of pregnancy were vaccinated in Italy (popula-
tion ~61 million) and 68,400 in the Netherlands
(population ~17 million). The differences in vaccination
rates detected between countries with similar vaccina-
tion policies might be related to different public percep-
tions of factors such as the vaccination campaign,
vaccine safety and the risk of the influenza pandemic. In
addition, inclusiveness and funding of different health
systems and implementation issues associated with the
delivery of different vaccination policies and associated
education campaigns might have been influential.
Furthermore, the decision to use vaccination centres
instead of general practitioners for vaccination may have
lowered the uptake of vaccination in some countries,
such as France [19].
Table 2 Vaccination policy overview by country for pregnant women and the general population
Country Vaccination strategy for Pregnant women Vaccination strategy for the general population
Policy Trimesters Vaccines1
1 2 3
Austria Yes ⊠ ⊠ Cev The entire population was offered the vaccine and certain groups4 were prioritized
Belgium Yes ⊠ ⊠ Pad Priority groups only4
Czech Republic2 No No
Croatia3 No No
Denmark Yes ⊠ ⊠ Pad Priority groups only4
Finland Yes ⊠ ⊠ ⊠ Pad The entire population was offered the vaccine and certain groups4 were prioritized
France Yes ⊠ ⊠ Pan The entire population was offered the vaccine and certain groups4 were prioritized
Germany Yes ⊠ ⊠ Pad, PIV [14] The entire population was offered the vaccine and certain groups4 were prioritized
Greece Yes ⊠ ⊠ Foc, Pad The entire population was offered the vaccine and certain groups4 were prioritized
Hungary Yes ⊠ ⊠ ⊠ Flu The entire population was offered the vaccine and certain groups4 were prioritized
Ireland Yes ⊠ ⊠ Cev, Pad The entire population was offered the vaccine and certain groups4 were prioritized
Italy Yes ⊠ ⊠ Foc The entire population was offered the vaccine and certain groups4 were prioritized
Latvia No No
Malta Yes ⊠ ⊠ ⊠ Pad The entire population was offered the vaccine and certain groups4 were prioritized
Netherlands Yes ⊠ ⊠ Foc Priority groups only4
Norway Yes ⊠ ⊠ Cev, Pad The entire population was offered the vaccine and certain groups4 were prioritized
Poland No No
Portugal Yes ⊠ ⊠ Pad Priority groups only4
Slovakia Yes ⊠ ⊠ ⊠ Pan The entire population was offered the vaccine and certain groups4 were prioritized
Slovenia Yes ⊠ ⊠ ⊠ Cev, Pad The entire population was offered the vaccine and certain groups4 were prioritized
Spain Yes ⊠ ⊠ ⊠ Pan Priority groups only4
Sweden Yes ⊠ ⊠ ⊠ Pad The entire population was offered the vaccine and certain groups4 were prioritized
Switzerland Yes ⊠ ⊠ Cel, Foc The entire population was offered the vaccine and certain groups4 were prioritized
United Kingdom Yes ⊠ ⊠ ⊠ Cev, Pad Priority groups only4
1Cel = Celtura® (Novartis), Cev = Celvapan® (Baxter), Flu = Fluval P® (Omnivest), Foc = Focetria® (Novartis), Pad = Pandemrix® (Glaxo Smith Kline), Pan =
Panenza® (Sanofi Pasteur), PIV = CSL Pandemic Influenza Vaccine® (CSL Biotherapies). Of these vaccines Celtura, Fluval P, Focetria and Pandemrix are adjuvanted
while Celvapan, Panenza and CSL Pandemic Influenza Vaccine are non-adjuvanted. Celtura, Fluval P, Focetria, Pandemrix, Panenza and CSL Pandemic Influenza
Vaccine contain Thiomersal while Celvapan does not contain Thiomersal.
2In Czech Republic the Pandemrix vaccine was unofficially recommended to pregnant women of 2nd and 3rd trimester and a small number of pregnant women
were vaccinated. The vaccine was offered to the general population. There was no official vaccination policy.
3In Croatia, pregnant woman of 2nd and 3rd trimester and the general population could apply for vaccination with the Focetria vaccine via health insurance and a
small number of pregnant women were vaccinated. There was no official vaccination policy.
4Priority groups include one or more of the following groups: pregnant women, health care workers, persons suffering from specific co-morbidities and/or people
working in essential public services.
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Table 3 Pandemic 2009 H1N1 influenza vaccination coverage of pregnant women; available data per European country
Country
(births
2009*[34])
EMA-NUI Information provided via EUROCAT Other information
Austria
(76033)
0 to 24%. Based on personal estimation
Belgium
(126886)
No exposure data available Unknown to registry.
Czech
Republic
(118283)
No exposure data available Unknown to registry.
Croatia
(44794)
Only 20 pregnant women have undergone vaccination. Data from
Croatian Institute of Public Health, Epidemiology unit
Denmark
(62831)
Weekly for Pandemrix: 5770 up to February 2010.
WCBA: 42546 up to February 2010.
Unknown to registry.
Finland
(60187)
No exposure data available 51.2% of mothers giving birth October-December 2009 were vaccinated
with Pandemrix according to the Finnish medical birth register.
France
(823925)
No exposure data available. WBCA: 980000
women aged 18-44 years old were vaccinated.
1) 25 to 49%. Based on CoFluPreg study (maternity wards in Paris) [12]. 2)
Vaccination was not yet available at the time of pandemic wave (weeks
30-38) for Isle de la Reunion [35].
22.7% up to January 2010. Data from French State
Health Insurance Fund [9]. 37.1% between Oct 2009 and
Feb 2010. Data from COFLUPREG study [12].
Germany
(664219)
0 to 24%. Based on registry and the Robert Koch Institute 8.8% between week 47/2009 and 14/2010. Based on 65
pregnant women [15].
Greece
(118234)
Weekly for Focetria (1382 up to January 2010)
and Pandemrix (751 up to January 2010)
Hungary
(96297)
17200 vaccinated About 16% [10].
Ireland
(73870)
Several cut-off points for combined Celvapan
and Pandemrix vaccination doses (31093 by June
2010).
A cross-sectional telephone survey found an uptake of 67% in pregnant
women (n = 1725)[36] while the National Summary of Pandemic
Influenza Vaccination estimates a vaccination rate of 32.5% [37].
Italy
(570428)
Weekly for Focetria (23016 up to week 23/2010)
Latvia
(21708)
No vaccinations took place No vaccinations took place
Malta (4136) 0 to 24%. Based on national vaccination register data (numerator:
persons classified as pregnant when vaccinated, denominator: number of
persons pregnant on 1/1/2009 [data for 2010 not yet available]
Netherlands
(184641)
Focetria exposure n = 68400 (cut-off 09 Feb
2010), Pandemrix 0
No registration was done of pregnant women who were vaccinated.
Currently a study is being undertaken to estimate the vaccine coverage
and to determine if the vaccine coverage depended on gestational age
or underlying illness. The study is being conducted by the RIVM and
14,000 women will be approached for this study.
Norway
(61430)
An estimated 70% of the pregnant women were
vaccinated. Monthly for Celvapan (49) for WCBA
and Pandemrix (377528) for WCBA.
1) 50 to 74%. The estimates is based on a small web-based request to
general practitioners, http://www.uib.no/isf/eyr
2) 75 to 99%. Based on vaccination registers vs. registers of pregnant
women. In the national registering system for vaccines there is no box
for pregnancy. The Pregnancy record, in use by all pregnant women is
being filled in manually.
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Table 3 Pandemic 2009 H1N1 influenza vaccination coverage of pregnant women; available data per European country (Continued)
Poland
(415681)
No vaccinations took place No vaccinations took place
Portugal
(99896)
0 to 24%. Based on national registry. Available national data from ACSS -
Administração Central do Sistema de Saúde, IP
Slovakia
(61158)
No exposure data available
Slovenia
(21746)
262 vaccinated total
Spain
(494944)
Weekly for Panenza (39183). 0 to 24%. Based on personal estimation. 4.7% uptake in Castilla and Leon regions [13].
Sweden
(111076)
15195 pregnant women and 264326 WCBA were
vaccinated in Stockholm county up to Feb 2010.
Switzerland
(77789)
Unknown to registry.
United
Kingdom
(788417)
103680 doses of Pandemrix and 1141 doses of
Celvapan. Likely an underestimation.
1) 50-74% were offered the vaccine according to primary care data from
a UKTIS study [16]. 2) 25 to 49%. Guess/Estimate based on proportion of
regional clinical at risk groups vaccinated.
Out of 2,061 women pregnant between September
2009 and January 2010, 64.8% were offered vaccination
and 25.2% were vaccinated [16].
Note the questions asked differed slightly between the NUI and the EUROCAT questionnaire. The competent authorities were asked to provide any weekly or monthly vaccination data that were available. The
EUROCAT member were asked to estimate the percentage of pregnant women vaccinated (see methods) and were requested to provide any vaccination data they had available.
WBCA: Women of childbearing age.
* Annual births 2009 given for comparison with numbers vaccinated. Note that numbers eligible for vaccination is the sum of the pregnant women in the relevant stage of pregnancy at initiation of the vaccination
campaign plus the pregnant women entering the relevant stage of pregnancy during the vaccination campaign.
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Varying pandemic influenza vaccine uptake rates have
been reported for pregnant women. In our survey, three
countries reported uptake above 50%. Uptake by preg-
nant women was reported as 6.9% in an Australian sur-
vey [20], 25.2% in a British survey [16], 76% in a
Canadian survey [21], 22.7% and 37.1% in French sur-
veys [9,12] and 8.8% in a German survey [15]. Factors
associated with vaccine uptake in the Canadian survey
were late stage of pregnancy, belief in the efficacy of the
vaccine, and consultation of the (Canadian) pandemic
influenza website. Factors negatively associated with vac-
cine uptake in the Canadian survey were belief that the
vaccine has not been adequately tested and consultation
of popular websites. The Australian survey concluded
the main reasons for the low vaccine uptake were the
vaccine frequently not being offered by the general prac-
titioner and safety concerns both of the women and the
general practitioners. In the British study, vaccination was
offered to 64.8% of the pregnant women. In their review of
the pandemic experience, the ECDC state the lack of vac-
cine acceptance can partially be attributed to the complex
risk message communicated. This risk message communi-
cated on the one hand that for people outside risk groups
the risk of severe disease was low, but on the other hand it
communicated that there was a small but real risk of
severe disease and death for healthy adults and children
[22]. In one American study, vaccination rates of pregnant
women with seasonal influenza vaccine were shown to
increase from 19% to 31% through increasing patient
awareness via education of vaccination providers and pos-
ters, underlining the impact of patient awareness in vacci-
nation campaigns [23]. A literature review found low
vaccination rates of pregnant women in countries where
seasonal influenza vaccination is recommended, ranging
from > 0.1% to 12.8% [24].
While in most countries it was decided to vaccinate
pregnant women of the second and third trimester, one of
the main differences between vaccination policies was the
decision whether to vaccinate pregnant women in the first
trimester of pregnancy. This difference between countries
on whether to vaccinate first trimester pregnant women
has also been witnessed in seasonal influenza vaccination
policies [1]. The first trimester of pregnancy is the period
of major organogenesis and thus important in relation to
risk of congenital anomalies, increasing the potential risk
of vaccination. In addition, women in the first trimester of
pregnancy are less susceptible to adverse health outcomes
caused by influenza infection, decreasing the benefit of
vaccinating this group. Differences in trimesters covered
by the pandemic vaccination policy might have been
caused by differences in appreciation of available safety
and efficacy data, or more operational reasons such as
potential for limited length of vaccine efficacy and wanting
it to be most effective in the later two trimesters, or
deciding that targeting women regardless of trimester
would better ensure high coverage by the start of the sec-
ond trimester. Post-pandemic immunogenicity data on
Pandemrix in healthcare workers showed that three
months post vaccination, 84% of the participants still had
a protective antibody titre (HI titre ≥40) compared to 97%
three weeks post vaccination [25]. Both figures are still
well above the Committee for Medicinal Products for
Human use (CHMP) criteria for seasonal vaccines of >
70% of the subjects achieving an HI titre of ≥40.
Whatever the policy regarding first trimester vaccina-
tion, where the entire population is offered vaccine, this
will include WCBA who are in the early stages of preg-
nancy but do not yet know they are pregnant. Other target
groups such as women with asthma, or health care work-
ers and persons in close contact with vulnerable groups
would also include women in very early pregnancy. These
women need to be taken into account when monitoring
vaccine safety in pregnancy. In addition, 1st trimester preg-
nant women belonging to priority groups or specifically
requesting for vaccination, could receive the vaccination in
some countries that did not routinely vaccinate 1st trime-
ster pregnant women.
Differences between countries were found in vaccines
used in pregnancy, including use of adjuvanted or non-
adjuvanted vaccines and Thiomersal content. Some
European pandemic vaccines were developed and regis-
tered pre-pandemic using a “mock-up” registration proce-
dure [26]. This procedure assumes that swapping the
strain in a vaccine will not substantially affect the safety
and efficacy of the vaccine. The mock up vaccines would
be authorized once a pandemic is declared, after which the
initial strain is swapped for the pandemic influenza strain.
Preliminary data on the immunogenicity of the monova-
lent non-adjuvanated and MF59-adjuvanated vaccines
showed favorable results [27,28]. These clinical trials also
demonstrated a single dose of the pandemic vaccine
would be sufficient for an immunogenic response, allow-
ing for antigen saving vaccination strategies. Several coun-
tries had established “advance purchase agreements” with
manufacturers, leading to some of the differences in vac-
cine chosen [26]. In these contracts, the manufacturer
agrees to supply its pandemic influenza vaccine as soon as
possible after a pandemic has been declared and agree to
reserve an agreed number of doses for the country. Coun-
try of origin of the manufacturer might have played a role
in vaccine of choice, as is illustrated by Hungary making
use of Fluval P, manufactured by the Hungarian company
Omninvest. Other possible factors in choice of vaccine
might originate in limited supplies available and differing
appreciation of available safety and efficacy data. Several of
the pandemic vaccine formulations included oil-in-water
adjuvants (AS03 for Pandemrix and MF59 for Celtura and
Focetria) or aluminium phosphate gel adjuvants (Fluval P)
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as an antigen saving policy [29] and to enhance the immu-
nogenicity of the pandemic vaccine. Celvapan, CSL Pan-
demic Influenza Vaccine and Panenza did not contain
adjuvants. Safety information of AS03 and MF59 adjuvants
is sufficient in the general population, but limited in preg-
nancy [29,30]. Five countries solely used non-adjuvanted
vaccine to vaccinate pregnant women. Some other coun-
tries used non-adjuvanted vaccines for the entire popula-
tion (table 2). Celvapan was the only pandemic vaccine
not to contain Thiomersal. No consensus has been
reached on the risk of prenatal exposure to Thiomersal
[31]. Both the AS03 and MF59 adjuvants contain squalene
[29,32]. We included questions about the timeframe of the
vaccination policy. There was variation in the speed of
response and in at least one case the vaccines arrived after
the vaccination campaign had been initiated. Vaccination
campaigns were initiated between 28th September 2009
and 27th December 2009, while the first pandemic wave
hit Europe in September-October 2009.
Post marketing surveillance of vaccines and medicinal
products is essential, in particular with regard to their
use in pregnancy since pregnant women are excluded
from clinical trials and much of the prior safety testing.
There are a number of different ways of carrying out
post marketing surveillance, including case-control stu-
dies of adverse pregnancy outcomes, and cohort studies
of women receiving the vaccine, but it is also essential
to collect basic information about exposure of pregnant
women in the population to the vaccine in order to
interpret any possible changes in population rates of
adverse pregnancy outcomes. The limited availability of
exposure data and the variation in quality of the avail-
able exposure data collected on pregnant women in
relation to the pandemic vaccine are striking, but in line
with the observed lack of exposure data of pregnant
women to seasonal influenza vaccination in Europe
[18,33]. This problem is further complicated by the need
to distinguish between first trimester of pregnancy and
second and third trimester of pregnancy, when exploring
the relationship between influenza vaccination and con-
genital anomalies. Pre-pandemic safety data of the pan-
demic vaccines and adjuvants used in the pandemic
vaccines in pregnancy is fairly limited. In order to con-
duct population based pharmacovigilance, exposure data
is needed to interpret congenital anomaly rates. A num-
ber of countries reported cohort studies being con-
ducted in pregnant women e.g. a national cohort in
Norway. The lack of comprehensive data on exposure of
pregnant women to pandemic influenza vaccine also
limits the policy evaluation process, which is required in
order to learn from the vaccination efforts for future
pandemic infectious disease outbreaks and vaccination
campaigns.
Conclusions
Overall, we conclude pandemic vaccination policies for
pregnant women in Europe were heterogeneous and
achieved varying vaccination rates of pregnant women.
Only limited data on exposure of pregnant women to
pandemic influenza vaccine was available in Europe. For
the evaluation of vaccine safety and adjuvants safety in
pregnancy and pandemic vaccination campaign effec-
tiveness, increased monitoring of pandemic influenza
vaccine coverage of pregnant women is required.
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